For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events ...

What Is Refractory Multiple Myeloma? Multiple myeloma is a cancer that affects a type of white blood cell called a plasma cell, which helps your immune system fight infections. Refractory means ...

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

While there is no cure for multiple myeloma, increased awareness about the symptoms can be the key to timely diagnosis and ...

Minimal residual disease (MRD) is a key focus in multiple myeloma treatment decision-making, offering prognostic insights and potential treatment guidance. Clinicians use MRD variably, with some ...

The Da Nang Hospital announced on March 31 that its department of neurology – musculoskeletal – clinical hematology has ...

New Innovative Local Treatment for Osteolytic Bone Disease in Multiple Myeloma Jan ... Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec. 5, 2024 — The first comprehensive ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

British biotech CellCentric is settling into a new office in Boston, part of the company’s expansion into the U.S. as ...

In a bid to provide comprehensive and patient-centered care for both cancerous and non-cancerous blood disorders, Fortis ...

Nearly everyone with multiple myeloma relapses. That doesn’t make it easy. A cancer diagnosis is traumatic, especially when the cancer is treatable, but not curable. In multiple myeloma, the disease ...